Leja Mārcis, You Weicheng, Camargo M Constanza, Saito Hiroshi
Faculty of Medicine, University of Latvia, 6 Linezera iela, LV1006 Riga, Latvia.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing 100142, PR China.
Best Pract Res Clin Gastroenterol. 2014 Dec;28(6):1093-106. doi: 10.1016/j.bpg.2014.09.005. Epub 2014 Sep 28.
Gastric cancer (GC) is still an important global healthcare problem, and in absolute figures it is going to remain at the present level in foreseeable future. In general, survival of patients with GC is poor mainly due to advanced-stage diagnosis. Early-stage GC can be cured by endoscopic resection or less invasive surgical treatment. Unfortunately, there is no appropriate screening strategy available for global application. This article provides a description of established national and regional GC screening programs and the screening modalities used. This review also summarizes current approaches to develop cancer-screening biomarkers. Although candidates with initial promising results have been suggested, moving discovery into clinical practice is still a major challenge. Well-designed biomarker studies, with systematic validation steps, are needed to decrease the burden of this fatal disease.
胃癌(GC)仍然是一个重要的全球医疗保健问题,从绝对数字来看,在可预见的未来它将维持在目前的水平。总体而言,GC患者的生存率较低,主要原因是诊断时已处于晚期。早期GC可通过内镜切除或微创外科治疗治愈。不幸的是,目前尚无适用于全球的合适筛查策略。本文介绍了已确立的国家和地区GC筛查计划以及所使用的筛查方式。本综述还总结了当前开发癌症筛查生物标志物的方法。尽管已经提出了一些初步结果令人鼓舞的候选生物标志物,但将其发现转化为临床实践仍然是一项重大挑战。需要设计完善的生物标志物研究,并采取系统的验证步骤,以减轻这种致命疾病的负担。